Top 5 Topical Carbonic Anhydrase Inhibitors for Dogs in Canada — 2026 Veterinary Guide to Trusopt, Azopt, Cosopt and Generics for Safer IOP Control
Published on Monday, February 2, 2026
Topical carbonic anhydrase inhibitors (CAIs) lower intraocular pressure (IOP) by inhibiting the carbonic anhydrase enzyme in the eye and are applied directly to the canine eye. Common veterinary formulations include dorzolamide and brinzolamide, used alone or combined with other classes such as beta-blockers. This category is appealing to Canadian pet owners and veterinarians because topical CAIs offer targeted pressure reduction with reduced systemic exposure, multiple branded and generic options for cost flexibility, and formulations that support convenient at-home dosing. In Canada, demand is driven by greater awareness of early glaucoma detection, increasing access to veterinary ophthalmology via regional clinics and telemedicine consultations, and price sensitivity that favors high-quality generics and combination products when appropriate.
Top Picks Summary
Trusopt (Dorzolamide) 2% Ophthalmic Solution
Trusopt is the reference-brand dorzolamide 2% aqueous solution with a long clinical track record and predictable topical carbonic anhydrase inhibition that veterinarians rely on for dogs. Its sterile solution formulation is easy to instill and generally causes less transient visual disturbance than suspensions, making it a practical and cost-effective branded choice compared with combination products and some suspension-based alternatives.
Azopt (Brinzolamide) 1% Ophthalmic Suspension
Azopt is the market-leading brinzolamide 1% suspension, valued in canine ophthalmology for a formulation that can be more comfortable and less stinging than acidic aqueous solutions. Compared with dorzolamide brands, Azopt often provides similar carbonic anhydrase inhibition with a distinct suspension profile — a technical advantage for tolerability in some dogs but sometimes at a higher branded price than generic monotherapies.
Cosopt (Dorzolamide-Timolol) Ophthalmic Solution
Cosopt pairs dorzolamide with timolol to deliver combined CAI and beta-blocker effects in a single bottle, offering stronger intraocular pressure reduction potential for dogs than CAI monotherapy. Although typically more expensive and requiring attention to systemic beta-blocker considerations in veterinary patients, Cosopt’s combination dosing reduces administration complexity and can improve adherence and overall cost-effectiveness where dual-mechanism control is indicated.
Dorzolamide 2% Generic Ophthalmic Solution
Generic dorzolamide 2% solutions provide the same active CAI ingredient as Trusopt but at lower acquisition cost, making them a budget-friendly option for long-term topical management of glaucoma in dogs. Manufacturing differences in preservatives and bottle design can slightly affect comfort, dosing convenience, or shelf life, but generics generally match branded pharmacologic efficacy while delivering meaningful financial savings for clinics and owners.
$20-50 CAD
Brinzolamide 1% Generic Ophthalmic Suspension
Generic brinzolamide 1% suspensions reproduce Azopt’s active profile at reduced cost, offering an economical suspension option for canine patients who tolerate particulate formulations. Variability in particle size and viscosity across suppliers can influence transient blur or dosing consistency, yet generics remain attractive for practices seeking lower-cost brinzolamide therapy while accepting slight formulation trade-offs compared with the Azopt benchmark.
$25-60 CAD
What the Research and Clinical Experience Say
Clinical studies and veterinary reports support the use of topical dorzolamide and brinzolamide for lowering IOP in dogs, with established safety profiles when dosed under veterinary supervision. Research also shows additive benefits when CAIs are combined with other topical agents (for example, timolol), and highlights practical considerations such as dosing frequency, tolerability, and the role of preservatives. The science is accessible for pet owners: topical CAIs reduce aqueous humor production by blocking the carbonic anhydrase enzyme in ocular tissues, resulting in measurable and often clinically meaningful reductions in IOP.
Efficacy: Controlled studies and veterinary case series report clinically meaningful reductions in IOP with topical dorzolamide and brinzolamide in dogs; combination therapy (dorzolamide plus timolol) typically achieves greater reductions than a CAI alone.
Onset and duration: Topical CAIs usually show IOP-lowering onset within hours, with typical dosing intervals ranging from two to three times daily depending on product and disease severity.
Safety: Systemic absorption is limited relative to oral CAIs, so systemic side effects are uncommon; ocular irritation and transient stinging are the most commonly reported local effects.
Preservatives and ocular surface health: Products containing preservatives such as benzalkonium chloride may exacerbate chronic ocular surface disease; preservative-free or lower-preservative options are preferred for long-term administration.
Practical outcomes: Studies and clinical practice emphasize adherence, correct drop administration, and regular IOP monitoring to preserve vision—owner education significantly improves outcomes.
Regulatory and access notes: In Canada, these medications are prescription-only; veterinarians may recommend branded or generic formulations and, in some cases, compounded alternatives when standard options are unavailable.
Frequently Asked Questions
Which topical CA inhibitor is best for most dogs?
For most dogs needing dorzolamide-based IOP control, Trusopt (Dorzolamide) 2% Ophthalmic Solution is a common clinic staple with an average rating of 4.2 and dorzolamide 2% topical carbonic anhydrase inhibition.
Does Azopt require shaking before each use?
Yes—Azopt (Brinzolamide) 1% Ophthalmic Suspension is a suspension formulation that requires shaking before use to ensure uniform dosing; it’s brinzolamide 1% topical carbonic anhydrase inhibition with an average rating of 4.3.
How does Cosopt price compare to single-agent options?
The provided data doesn’t list any prices, so I can’t compare Cosopt to Trusopt or Azopt by cost in Canada; what’s provided is Cosopt’s average rating of 4.1 and its dorzolamide–timolol dual mechanism.
Is Cosopt for dogs needing both CAI and beta-blocker effects?
Cosopt (Dorzolamide-Timolol) Ophthalmic Solution is for canine glaucoma management when both mechanisms are indicated, combining dorzolamide carbonic anhydrase inhibition with timolol beta-blockade in one bottle; average rating is 4.1.
Conclusion
In the Canadian 2026 context, topical carbonic anhydrase inhibitors remain a cornerstone for managing canine glaucoma. The five featured options on this page — Trusopt (Dorzolamide) 2% Ophthalmic Solution, Azopt (Brinzolamide) 1% Ophthalmic Suspension, Cosopt (Dorzolamide-Timolol) Ophthalmic Solution, Dorzolamide 2% Generic Ophthalmic Solution, and Brinzolamide 1% Generic Ophthalmic Suspension — each have roles depending on clinical needs, cost considerations, and tolerance. For many dogs, Trusopt (Dorzolamide) 2% Ophthalmic Solution is a solid first-line choice because of its established efficacy and veterinary familiarity; Cosopt is often the preferred next step when additional IOP lowering is required through combination therapy. Azopt and the generic dorzolamide and brinzolamide products provide effective and more budget-conscious alternatives. I hope you found this guide useful — refine or expand your search by product name, formulation, or dosing needs to find the best option for your dog, and consult your veterinarian for diagnosis and a tailored treatment plan.